Happy Holidays to all. Please Note: There will be no meeting on New Year's Day

CAR-T used in treatment of two men with mCRPC at UPenn

by Jim Barney on January 14, 2018


On a CureTalks conversation with Dr. Carl June of the University of Pennsylvania (UPenn), we learned that his team had very recently treated two men with metastatic, castration-resistant prostate cancer (mCRPC) using chimeric antibody receptor T-cell therapy (CAR-T).

Read the article here.

{ 0 comments… add one now }

Previous post:

Next post: